SRR934739
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.606
- IL6_JAK_STAT3_SIGNALING+0.566
- INFLAMMATORY_RESPONSE+0.548
- ALLOGRAFT_REJECTION+0.513
- ANGIOGENESIS+0.417
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.413
- COAGULATION+0.383
- INTERFERON_GAMMA_RESPONSE+0.353
- COMPLEMENT+0.326
- HYPOXIA+0.321
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.363
- OXIDATIVE_PHOSPHORYLATION-0.355
- MITOTIC_SPINDLE-0.279
- WNT_BETA_CATENIN_SIGNALING-0.261
- ADIPOGENESIS-0.231
- MYOGENESIS-0.223
- NOTCH_SIGNALING-0.220
- PEROXISOME-0.195
- CHOLESTEROL_HOMEOSTASIS-0.188
- FATTY_ACID_METABOLISM-0.163
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934872 | — | — | 0.943 |
| 2 | SRR934894 | — | — | 0.887 |
| 3 | SRR934794 | — | — | 0.856 |
| 4 | SRR934785 | — | — | 0.833 |
| 5 | SRR934781 | — | — | 0.830 |
| 6 | SRR817658 | GTEX | — | 0.821 |
| 7 | SRR1453932 | GTEX | — | 0.815 |
| 8 | SRR8613745 | — | A | 0.809 |
| 9 | 2c1c1b9c-180d-44af-b62a-ca9d83ae993f | — | — | 0.808 |
| 10 | SRR934784 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.606 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.566 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.548 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.513 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.417 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.413 | Inavolisib | — uncovered |
| COAGULATION | 0.383 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.353 | Idelalisib | — uncovered |
| COMPLEMENT | 0.326 | Inavolisib | — uncovered |
| HYPOXIA | 0.321 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.286 | Idelalisib | — uncovered |
| APOPTOSIS | 0.284 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.271 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.233 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.205 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.201 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.165 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.142 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.134 | Inavolisib | — uncovered |